SS
Santosh Shrikrishna Joshi
About Santosh Shrikrishna Joshi
Data last updated:
Santosh Shrikrishna Joshi is a Director at Prowill Pharmaceuticals Private Limited (since 2020), Director at Allcure Health Care Private Limited (since 2010) and Director at Accon Lifesciences Private Limited (since 2013), and holds 1 more current directorship. The companies operate in Pharma, Chemicals and Trading. The 4 current companies with reported revenue have a combined latest revenue of ₹6.74 Cr; the largest is Prowill Pharmaceuticals Private Limited at ₹6.03 Cr (FY 2025). Earlier, Santosh Shrikrishna Joshi was a Director at Sequel Pharmaceuticals (India) Private Limited (2006–2023) and Director at Accutest Research Laboratories India Private Limited (2001–2015) and 2 more.
Current companies
| Company | Designation | Appointment | Founded | Revenue | Status |
|---|---|---|---|---|---|
| Director | 17 Jul 2020 | 2012 | ₹6.03 Cr (FY 2025) | Active | |
| Director | 21 Sep 2010 | 2010 | ₹70.1 Lakh (FY 2025) | Active | |
| Director | 18 Apr 2013 | 2013 | ₹74,756 (FY 2019) | Active | |
| Director | 23 Mar 2016 | 2015 | ₹18,370 (FY 2023) | Active |
Previous companies
| Company | Designation | Appointment | Founded | Revenue | Status |
|---|---|---|---|---|---|
| Director | 28 Jun 2006 | 2006 | Active | ||
| Director | 08 Mar 2001 | 2001 | ₹40.93 Cr (FY 2024) | Active | |
| Director | 03 Nov 2010 | 2010 | ₹3.00 Cr (FY 2022) | Active | |
| Director | 22 Oct 2010 | 2010 | ₹11,000 (FY 2018) | Strike Off |
Explore Director's current and past company associations Uncover their professional journey today!
Board colleagues of Santosh Shrikrishna Joshi
| Name | DIN | Company | Designation |
|---|---|---|---|
| Varsha Santosh Joshi | 02043099 | Prowill Pharmaceuticals Private Limited , Allcure Health Care Private Limited | Director |
| Santosh Shantaram Palkar | 08285839 | Accon Lifesciences Private Limited | Director |
| Amol Ramdas Nilakh | 07304539 | Symlux Pharmaceuticals Private Limited | Director |
Directorship timeline
Open interactive timeline →Shareholding and investment profile for Santosh Shrikrishna Joshi
Company-level share counts, filed values, and quarterly changes require authenticated premium access.
- Company-level holdings
- Filed share counts
- Reported values
- Quarterly changes
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Santosh Shrikrishna Joshi
Santosh Shrikrishna Joshi currently holds 4 directorships: Prowill Pharmaceuticals Private Limited (Director, since 17 Jul 2020, revenue ₹6.03 Cr (FY 2025)); Allcure Health Care Private Limited (Director, since 21 Sep 2010, revenue ₹70.1 Lakh (FY 2025)); Accon Lifesciences Private Limited (Director, since 18 Apr 2013, revenue ₹74,756 (FY 2019)); Symlux Pharmaceuticals Private Limited (Director, since 23 Mar 2016, revenue ₹18,370 (FY 2023)).
Santosh Shrikrishna Joshi was first appointed on 08 Mar 2001 as Director at Accutest Research Laboratories India Private Limited. The most recent appointment on record is 17 Jul 2020 at Prowill Pharmaceuticals Private Limited.
The 4 current companies of Santosh Shrikrishna Joshi that report revenue have a combined latest revenue of ₹6.74 Cr: Prowill Pharmaceuticals Private Limited ₹6.03 Cr (FY 2025); Allcure Health Care Private Limited ₹70.1 Lakh (FY 2025); Accon Lifesciences Private Limited ₹74,756 (FY 2019); Symlux Pharmaceuticals Private Limited ₹18,370 (FY 2023).
Santosh Shrikrishna Joshi held 4 earlier board appointments: Sequel Pharmaceuticals (India) Private Limited (Director, 28 Jun 2006 to 08 May 2023); Accutest Research Laboratories India Private Limited (Director, 08 Mar 2001 to 07 Sep 2015); Vasundhara Mrk Infrastructure Private Limited (Director, 03 Nov 2010 to 20 Apr 2018); Poorvi Investments Private Limited (Director, from 22 Oct 2010).
The current boards of Santosh Shrikrishna Joshi's companies include Varsha Santosh Joshi (Prowill Pharmaceuticals Private Limited), Santosh Shantaram Palkar (Accon Lifesciences Private Limited), Amol Ramdas Nilakh (Symlux Pharmaceuticals Private Limited).